Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

Julie Graff, Celestia S. Higano, Noah M. Hahn, Matthew Taylor, Bin Zhang, Xiaofei Zhou, Karthik Venkatakrishnan, E. Jane Leonard, John Sarantopoulos

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BACKGROUND: This study was designed to determine the safety, tolerability, and pharmacokinetics (PK) of alisertib (MLN8237) in combination with docetaxel and to identify a recommended dose for the combination. METHODS: Adults with metastatic cancer were treated on 21-day cycles with alisertib (10, 20, 30, or 40 mg) twice daily on days 1 to 7 or days 1 to 5 and with docetaxel (75 or 60 mg/m2) on day 1. The primary objectives were to assess the safety and tolerability of the combination and to determine the recommended phase 2 dose (RP2D) for future studies. Secondary objectives included an efficacy assessment and PK analyses of docetaxel and alisertib. RESULTS: Forty-one patients participated. Eight dose levels were explored with various doses of alisertib and docetaxel. The dose-limiting toxicities were neutropenic fever, neutropenia without fever, stomatitis, and urinary tract infection. The RP2D of this combination was 20 mg of alisertib twice daily on days 1 to 7 and intravenous docetaxel at 75 mg/m2 on day 1 in 21-day cycles. Eight of the 28 patients (29%) who were efficacy-evaluable had objective responses. These included 1 complete response in a patient with bladder cancer, 6 partial responses in patients with castration-resistant prostate cancer, and 1 partial response in a patient with angiosarcoma. Concomitant administration of alisertib did not produce any clinically meaningful change in docetaxel PK. CONCLUSIONS: Alisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m2 on day 1 in a 21-day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016;122:2524–33.

Original languageEnglish (US)
Pages (from-to)2524-2533
Number of pages10
JournalCancer
Volume122
Issue number16
DOIs
StatePublished - Aug 15 2016

Fingerprint

docetaxel
Aurora Kinase A
Neoplasms
Pharmacokinetics
Fever
Safety
Stomatitis
Hemangiosarcoma
MLN 8237
Castration
Neutropenia
Urinary Bladder Neoplasms
Urinary Tract Infections

Keywords

  • alisertib
  • aurora A kinase
  • novel antitumor agents
  • pharmacokinetics/pharmacodynamics
  • solid tumors

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors. / Graff, Julie; Higano, Celestia S.; Hahn, Noah M.; Taylor, Matthew; Zhang, Bin; Zhou, Xiaofei; Venkatakrishnan, Karthik; Leonard, E. Jane; Sarantopoulos, John.

In: Cancer, Vol. 122, No. 16, 15.08.2016, p. 2524-2533.

Research output: Contribution to journalArticle

Graff, J, Higano, CS, Hahn, NM, Taylor, M, Zhang, B, Zhou, X, Venkatakrishnan, K, Leonard, EJ & Sarantopoulos, J 2016, 'Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors', Cancer, vol. 122, no. 16, pp. 2524-2533. https://doi.org/10.1002/cncr.30073
Graff, Julie ; Higano, Celestia S. ; Hahn, Noah M. ; Taylor, Matthew ; Zhang, Bin ; Zhou, Xiaofei ; Venkatakrishnan, Karthik ; Leonard, E. Jane ; Sarantopoulos, John. / Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors. In: Cancer. 2016 ; Vol. 122, No. 16. pp. 2524-2533.
@article{abe609c4bfb1495f80ed77e04e147ca9,
title = "Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors",
abstract = "BACKGROUND: This study was designed to determine the safety, tolerability, and pharmacokinetics (PK) of alisertib (MLN8237) in combination with docetaxel and to identify a recommended dose for the combination. METHODS: Adults with metastatic cancer were treated on 21-day cycles with alisertib (10, 20, 30, or 40 mg) twice daily on days 1 to 7 or days 1 to 5 and with docetaxel (75 or 60 mg/m2) on day 1. The primary objectives were to assess the safety and tolerability of the combination and to determine the recommended phase 2 dose (RP2D) for future studies. Secondary objectives included an efficacy assessment and PK analyses of docetaxel and alisertib. RESULTS: Forty-one patients participated. Eight dose levels were explored with various doses of alisertib and docetaxel. The dose-limiting toxicities were neutropenic fever, neutropenia without fever, stomatitis, and urinary tract infection. The RP2D of this combination was 20 mg of alisertib twice daily on days 1 to 7 and intravenous docetaxel at 75 mg/m2 on day 1 in 21-day cycles. Eight of the 28 patients (29{\%}) who were efficacy-evaluable had objective responses. These included 1 complete response in a patient with bladder cancer, 6 partial responses in patients with castration-resistant prostate cancer, and 1 partial response in a patient with angiosarcoma. Concomitant administration of alisertib did not produce any clinically meaningful change in docetaxel PK. CONCLUSIONS: Alisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m2 on day 1 in a 21-day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016;122:2524–33.",
keywords = "alisertib, aurora A kinase, novel antitumor agents, pharmacokinetics/pharmacodynamics, solid tumors",
author = "Julie Graff and Higano, {Celestia S.} and Hahn, {Noah M.} and Matthew Taylor and Bin Zhang and Xiaofei Zhou and Karthik Venkatakrishnan and Leonard, {E. Jane} and John Sarantopoulos",
year = "2016",
month = "8",
day = "15",
doi = "10.1002/cncr.30073",
language = "English (US)",
volume = "122",
pages = "2524--2533",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "16",

}

TY - JOUR

T1 - Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

AU - Graff, Julie

AU - Higano, Celestia S.

AU - Hahn, Noah M.

AU - Taylor, Matthew

AU - Zhang, Bin

AU - Zhou, Xiaofei

AU - Venkatakrishnan, Karthik

AU - Leonard, E. Jane

AU - Sarantopoulos, John

PY - 2016/8/15

Y1 - 2016/8/15

N2 - BACKGROUND: This study was designed to determine the safety, tolerability, and pharmacokinetics (PK) of alisertib (MLN8237) in combination with docetaxel and to identify a recommended dose for the combination. METHODS: Adults with metastatic cancer were treated on 21-day cycles with alisertib (10, 20, 30, or 40 mg) twice daily on days 1 to 7 or days 1 to 5 and with docetaxel (75 or 60 mg/m2) on day 1. The primary objectives were to assess the safety and tolerability of the combination and to determine the recommended phase 2 dose (RP2D) for future studies. Secondary objectives included an efficacy assessment and PK analyses of docetaxel and alisertib. RESULTS: Forty-one patients participated. Eight dose levels were explored with various doses of alisertib and docetaxel. The dose-limiting toxicities were neutropenic fever, neutropenia without fever, stomatitis, and urinary tract infection. The RP2D of this combination was 20 mg of alisertib twice daily on days 1 to 7 and intravenous docetaxel at 75 mg/m2 on day 1 in 21-day cycles. Eight of the 28 patients (29%) who were efficacy-evaluable had objective responses. These included 1 complete response in a patient with bladder cancer, 6 partial responses in patients with castration-resistant prostate cancer, and 1 partial response in a patient with angiosarcoma. Concomitant administration of alisertib did not produce any clinically meaningful change in docetaxel PK. CONCLUSIONS: Alisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m2 on day 1 in a 21-day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016;122:2524–33.

AB - BACKGROUND: This study was designed to determine the safety, tolerability, and pharmacokinetics (PK) of alisertib (MLN8237) in combination with docetaxel and to identify a recommended dose for the combination. METHODS: Adults with metastatic cancer were treated on 21-day cycles with alisertib (10, 20, 30, or 40 mg) twice daily on days 1 to 7 or days 1 to 5 and with docetaxel (75 or 60 mg/m2) on day 1. The primary objectives were to assess the safety and tolerability of the combination and to determine the recommended phase 2 dose (RP2D) for future studies. Secondary objectives included an efficacy assessment and PK analyses of docetaxel and alisertib. RESULTS: Forty-one patients participated. Eight dose levels were explored with various doses of alisertib and docetaxel. The dose-limiting toxicities were neutropenic fever, neutropenia without fever, stomatitis, and urinary tract infection. The RP2D of this combination was 20 mg of alisertib twice daily on days 1 to 7 and intravenous docetaxel at 75 mg/m2 on day 1 in 21-day cycles. Eight of the 28 patients (29%) who were efficacy-evaluable had objective responses. These included 1 complete response in a patient with bladder cancer, 6 partial responses in patients with castration-resistant prostate cancer, and 1 partial response in a patient with angiosarcoma. Concomitant administration of alisertib did not produce any clinically meaningful change in docetaxel PK. CONCLUSIONS: Alisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m2 on day 1 in a 21-day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016;122:2524–33.

KW - alisertib

KW - aurora A kinase

KW - novel antitumor agents

KW - pharmacokinetics/pharmacodynamics

KW - solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84983000730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983000730&partnerID=8YFLogxK

U2 - 10.1002/cncr.30073

DO - 10.1002/cncr.30073

M3 - Article

C2 - 27192055

AN - SCOPUS:84983000730

VL - 122

SP - 2524

EP - 2533

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 16

ER -